Functional role of cannabinoid receptors in urinary bladder

Indian Journal of Urology

Volumn 26, Issue 1, 2010, Pages 26-35

  Tyagi, Pradeep ^a   Tyagi, Vikas ^a   Yoshimura, Naoki ^b   Chancellor, Michael ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Bladder; Cannabinoids; Irritation; Protein coupled receptor; Receptor expression

Indexed keywords

AJULEMIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOL; CANNABIS; CAPSAICIN; DRONABINOL; ENDOCANNABINOID; INDOMETACIN; LOCAL ANESTHETIC AGENT; NABILONE; PHYTOCANNABINOID DERIVATIVE; PLACEBO; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RESINIFERATOXIN; RIMONABANT; UNCLASSIFIED DRUG;

ANXIETY DISORDER; BLADDER; BULIMIA; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; CYSTALGIA; DIZZINESS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FATIGUE; GENITAL PAIN; HUMAN; INTERSTITIAL CYSTITIS; LOWER URINARY TRACT SYMPTOM; MOTOR DYSFUNCTION; MUSCLE SPASM; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PARANOIA; PELVIC DISEASE; PROTEIN EXPRESSION; PSYCHOSIS; PULMONARY IRRITATION; RESPIRATORY TRACT DISEASE; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPASTICITY; TACHYCARDIA; TASTE DISORDER; URETHRA; URINARY TRACT PAIN;

EID: 77950577198     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.60440     Document Type: Review

References (75)

1. Zuardi AW. History of cannabis as a medicine: A review. Rev Bras Psiquiatr 2006;28:153-157
2. Khiabani HZ, Bramness JG, Bjorneboe A, Morland J. Relationship between THC concentration in blood and impairment in apprehended drivers. Traffic Inj Prev 2006;7:111-116
3. Felder CC, Dickason-Chesterfield AK, Moore SA. Cannabinoids biology: The search for new therapeutic targets. Mol Interv 2006;6:149-161
4. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors 10.1124/pr.54.2.161. Pharmacol Rev 2002;54:161-202.
5. Ahluwalia J, Urban L, Bevan S, Capogna M, Nagy I. Cannabinoid 1 receptors are expressed by nerve growth factor-and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience 2002;110:747-753
6. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002;66:101-121
7. Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/ death decision by cannabinoids. J Mol Med 2001;78:613-625
8. Kumar AM, Solomon J, Patel V, Kream RM, Drieze JM, Millard WJ. Early exposure to delta 9-tetrahydrocannabinol influences neuroendocrine and reproductive functions in female rats. Neuroendocrinology 1986;44:260-264
9. Gye MC, Kang HH, Kang HJ. Expression of cannabinoid receptor 1 in mouse testes. Arch Androl 2005;51:247-255
10. Pertwee RG, Ross RA, Craib SJ, Thomas A.-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 2002;456:99-106.
11. Ruiz-Llorente L, Sanchez MG, Carmena MJ, Prieto JC, Sanchez-Chapado M, Izquierdo A, et al. Expression of functionally active cannabinoid receptor CB1 in the human prostate gland. Prostate 2003;54:95-102.
12. Aquila S, Guido C, Laezza C, Santoro A, Pezzi V, Panza S, et al. A new role of anandamide in human sperm: Focus on metabolism. J Cell Physiol 2009;221:147-153
13. Cabral GA. Localization of cannabinoid receptors using immuno peroxidase methods. Methods Mol Med 2006;123:41-69.
14. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: Evidence for new players. Aaps J 2006;8:E298-306.
15. Mechoulam R, Hanu L. The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 2001;6:67-73.
16. Stella N. Cannabinoid signaling in glial cells. Glia 2004;48:267-277
17. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005;435:1108-1112
18. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. Faseb J 2006;20:568-570
19. Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 2003;17:2611-2618
20. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005;83:944-954
21. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: A multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17:636:41.
22. Russo E, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234-246
23. Pertwee RG, Fernando SR. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 1996;118:2053-2058
24. Blyweert W, Van der Aa F, Ost D, Stagnaro M, De Ridder D. Interstitial cells of the bladder: The missing link? BJOG 2005;111:57.
25. Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol 2009;35:76-83.
26. Onaivi ES. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 2006;54:231-246
27. Martin RS, Luong LA, Welsh NJ, Eglen RM, Martin GR, MacLennan SJ. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharmacol 2000;129:1707-1715
28. Hayn MH, Ballesteros I, de Miguel F, Coyle CH, Tyagi S, Yoshimura N, et al. Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder. Urology 2008;72:1174-1178
29. Ellington HC, Cotter MA, Cameron NE, Ross RA. The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology 2002;42:966-975
30. Chancellor MB, Yoshimura N. Treatment of interstitial cystitis. Urology 2004;63:85-92.
31. Gabella G. Structure of the intramural nerves of the rat bladder. J Neurocytol 1999;28:615-637
32. Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: Expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol 2006;373:287-299
33. Kalsi V, Fowler CJ. Therapy Insight: Bladder dysfunction associated with multiple sclerosis. Nat Clin Pract Urol 2005;2:492-501.
34. Gratzke C, Streng T, Park A, Christ G, Stief CG, Hedlund P, et al. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol 2009;181:1939-1948
35. Su HC, Wharton J, Polak JM, Mulderry PK, Ghatei MA, Gibson SJ, et al. Calcitonin gene-related peptide immunoreactivity in afferent neurons supplying the urinary tract: Combined retrograde tracing and immunohistochemistry. Neuroscience 1986;18:727-747
36. Tyagi V, Philips BJ, Su R, Smaldone MC, Erickson VL, Chancellor MB, et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 2009;181:1932-1938
37. Ghasemi M, Sadeghipour H, Shafaroodi H, Nezami BG, Gholipour T, Hajrasouliha AR, et al. Role of the nitric oxide pathway and the endocannabinoid system in neurogenic relaxation of corpus cavernosum from biliary cirrhotic rats. Br J Pharmacol 2007;151:591-601. (Pubitemid 47016299)
38. Dinis P, Charrua A, Avelino A, Yaqoob M, Bevan S, Nagy I, et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 2004;24:11253-11263
39. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998;76:189-199
40. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-281
41. Morisset V, Ahluwalia J, Nagy I, Urban L. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur J Pharmacol 2001;429:93-100.
42. Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M, et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 2006;148:1022-1032
43. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: An overview. Int J Obes (Lond) 2006;30:S13-8.
44. Yesilyurt O, Dogrul A. Lack of cross-tolerance to the antinociceptive effects of systemic and topical cannabinoids in morphine-tolerant mice. Neurosci Lett 2004;371:122-127
45. Malan J, Philip T, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: Pain relief without psychoactive effects? Current Opinion in Pharmacology 2003;3:62-67
46. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain: [Les effets de la nabilone, un cannabinoide synthetique, sur la douleur postoperatoire]. Can J Anaesth 2006;53: 769-775
47. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 2006;7:25-29
48. Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. G uidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 2005;10:44A-6A.
49. Fisher BA, Ghuran A, Vadamalai V, Antonios TF. Cardiovascular complications induced by cannabis smoking: A case report and review of the literature. Emerg Med J 2005;22:679-680
50. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327-360
51. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007;316:1494-1497
52. Maekawa T, Nojima H, Kuraishi Y, Aisaka K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol 2006;542:179-183
53. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 2006;40:251-260
54. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425-433
55. Barnes MP. Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006;7:607-615
56. Dogrul A, Gul H, Akar A, Yildiz O, Bilgin F, Guzeldemir E. Topical canna binoid antinociception: Synergy with spinal sites. Pain 2003;105:11-16
57. Sokal DM, Elmes SJ, Kendall DA, Chapman V. Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 2003;45:404-411
58. Tyagi P, Tyagi S, Kaufman J, Huang L, de Miguel F. Local drug delivery to bladder using technology innovations. Urol Clin North Am 2006;33:519-530
59. Tyagi P, Chancellor MB, Li Z, De Groat WC, Yoshimura N, Fraser MO, et al. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol 2004;171:483-489
60. Chuang YC, Thomas CA, Tyagi S, Yoshimura N, Tyagi P, Chancellor MB. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:1353-1357
61. Chuang YC, Tyagi P, Huang CC, Yoshimura N, Wu M, Kaufman J, et al. Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Liposomes. J Urol 2009182:786-792
62. Tyagi V, Yoshimura N, Chancellor MB, Tyagi P. Local Activation Of Cannabinoid Cb1 Receptors Bladder Suppresses Acetic Acid Induced Bladder Irritation. J Urol 2008;179:539-554
63. Tyagi V, Yoshimura N, Chancellor MB, Tyagi P. Instillation of Selective CB2 Agonist Protects Against Bladder Irritation J Urol 2008;179:352.
64. Ganabathi R, Tyagi P, de Miguel F, Tyagi S, Yoshimura N, Chancellor MB. Effect of IP-751, Ajulemic Acid, against Acetic Acid Induced Bladder Pain Responses in Rats 24h After Intravesical Administration J Urol 2006;176:93-94
65. Dyson A, Peacock M, Chen A, Courade JP, Yaqoob M, Groarke A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 2005;116:129-137
66. Hiragata S, Ogawa T, Hayashi Y, Tyagi P, Seki S, Nishizawa O, et al. Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 2007;70:202-208
67. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. Handb Exp Pharmacol 2005;168:573-598
68. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: A comparative analysis. Br J Pharmacol 2007;150:153-163
69. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996;300:227-236
70. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB(1) and CB(2) receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007;152:765-777
71. Ossipov MH, Porreca F. Challenges in the development of novel treatment strategies for neuropathic pain. NeuroRx 2005;2:650-661
72. Dionne RA, Lepinski AM, Gordon SM, Jaber L, Brahim JS, Hargreaves KM. Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation. Clin Pharmacol Ther 2001;70:66-73.
73. Di Marzo V, Griffin G, De Petrocellis L, Brandi I, Bisogno T, Williams W, et al. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J Pharmacol Exp Ther 2002;300:984-991
74. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, et al. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 1999;65:627-635
75. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999;283:401-404